Bioengineering AG was acquired by the Japanese Morimatsu Group on 10 September 2025. With its new owner, Bioengineering aims to tap into new market opportunities, increase its investment in research, development and innovation, expand its headquarters in Wald/ZH and offer its employees international prospects. The "Bioengineering AG" brand will be retained, the headquarters in Wald/ZH will remain in place and will play an important role in the Morimatsu Group in the future. With its 53-year history, Bioengineering will continue to be active and successful on the international market.

Attractive prospects for employees and customers

Morimatsu is a global, diversified provider of complete solutions with around 5,000 employees worldwide and a trusted partner. It offers leading global pharmaceutical companies, CDMOs, FMCG (fast-moving consumer goods) companies, energy companies and other specialised industrial companies advanced modular plant solutions, high-precision process equipment and comprehensive integrated services. The new owner will offer Bioengineering appropriate development opportunities. This will enable Bioengineering's customers to order larger systems from their trusted supplier. The decision also offers employees exciting career and development opportunities on an international level.

Given the strong brand recognition of both companies, the merged entity will be well positioned to leverage synergies and tap into the market with a broader range of solutions, first-class services and higher-value offerings. Bioengineering's accumulated knowledge will be effectively utilised and integrated into Morimatsu's global technical expertise to continuously drive innovation initiatives and maintain a leading position through synergies and combined strengths.

Marcus Bernhardt, Vice-Chairman of the Board of Directors of Bioengineering AG, says of this decision: "It is very important to us that the philosophy of our new Japanese owner fits well with our culture. Thanks to the new owner and the opportunities this presents, we can build on our position of strength to develop the company into a top-class international player."

Wald/ZH to become Morimatsu's Swiss centre in Europe

Bioengineering's current headquarters in Wald/ZH is set to become Morimatsu's Swiss centre in Europe and play an important role within the group. Bioengineering will effectively leverage Morimatsu's global strength and create synergies to continuously drive innovation initiatives, guarantee advanced and high-quality products, and collaborate even more effectively with global customers and partners.

Terumoto Matsuhisa, Chairman of Morimatsu International Holdings Co., Ltd, explains: "Bioengineering has earned an excellent reputation in the biotech industry over more than 50 years. We have observed with interest how this company, a unique supplier to large pharmaceutical and chemical companies, has become successful in our industry. We expect and believe that this new journey, with our combined synergies, will lead to new successes and significant developments."

The parties have agreed to keep the purchase price confidential.